Merck and Moderna maintain a long-standing collaboration agreement on mRNA-based personalized cancer vaccines, including recent positive five-year Phase 2 follow-up data showing a 49% risk reduction in melanoma recurrence, but no ownership transaction has materialized or been signaled. Merck has pursued disciplined, smaller-scale acquisitions such as its $6.7 billion Terns deal while targeting transactions under $15 billion to offset the Keytruda patent cliff, rendering a full merger with Moderna’s roughly $25 billion market capitalization improbable. Absent regulatory filings, management commentary, or analyst indications of talks, trader consensus reflects these structural and strategic barriers, with upcoming Phase 3 readouts in 2026/2027 likely to reinforce the existing partnership rather than catalyze an acquisition announcement.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano20% szansa
NOWE
NOWE
Dec 31, 2026
20% szansa
NOWE
NOWE
Dec 31, 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a long-standing collaboration agreement on mRNA-based personalized cancer vaccines, including recent positive five-year Phase 2 follow-up data showing a 49% risk reduction in melanoma recurrence, but no ownership transaction has materialized or been signaled. Merck has pursued disciplined, smaller-scale acquisitions such as its $6.7 billion Terns deal while targeting transactions under $15 billion to offset the Keytruda patent cliff, rendering a full merger with Moderna’s roughly $25 billion market capitalization improbable. Absent regulatory filings, management commentary, or analyst indications of talks, trader consensus reflects these structural and strategic barriers, with upcoming Phase 3 readouts in 2026/2027 likely to reinforce the existing partnership rather than catalyze an acquisition announcement.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Rynek otwarty: Aug 19, 2026, 3:58 PM ET
Wolumen
$20Data zakończenia
Dec 31, 2026Rynek otwarty
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a long-standing collaboration agreement on mRNA-based personalized cancer vaccines, including recent positive five-year Phase 2 follow-up data showing a 49% risk reduction in melanoma recurrence, but no ownership transaction has materialized or been signaled. Merck has pursued disciplined, smaller-scale acquisitions such as its $6.7 billion Terns deal while targeting transactions under $15 billion to offset the Keytruda patent cliff, rendering a full merger with Moderna’s roughly $25 billion market capitalization improbable. Absent regulatory filings, management commentary, or analyst indications of talks, trader consensus reflects these structural and strategic barriers, with upcoming Phase 3 readouts in 2026/2027 likely to reinforce the existing partnership rather than catalyze an acquisition announcement.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Wolumen
$20Data zakończenia
Dec 31, 2026Rynek otwarty
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Merck and Moderna maintain a long-standing collaboration agreement on mRNA-based personalized cancer vaccines, including recent positive five-year Phase 2 follow-up data showing a 49% risk reduction in melanoma recurrence, but no ownership transaction has materialized or been signaled. Merck has pursued disciplined, smaller-scale acquisitions such as its $6.7 billion Terns deal while targeting transactions under $15 billion to offset the Keytruda patent cliff, rendering a full merger with Moderna’s roughly $25 billion market capitalization improbable. Absent regulatory filings, management commentary, or analyst indications of talks, trader consensus reflects these structural and strategic barriers, with upcoming Phase 3 readouts in 2026/2027 likely to reinforce the existing partnership rather than catalyze an acquisition announcement.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania